Nucleic acid quantification and disease outcome prediction in colorectal cancer

Personalized Medicine

Volumn 3, Issue 2, 2006, Pages 207-216

  Bustin, Stephen A ^a,b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Cancer; Colon; Metastasis; Microarray; Occult disease; Polymerase chain reaction; Reverse transcription; Staging

Indexed keywords

DNA; INTERCALATING AGENT; NUCLEIC ACID;

ARTICLE; AWARENESS; BONE MARROW METASTASIS; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER STAGING; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DNA DETERMINATION; DNA MICROARRAY; FLUORESCENCE ANALYSIS; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; INDIVIDUALIZATION; LYMPH NODE METASTASIS; NUCLEIC ACID ANALYSIS; OUTCOMES RESEARCH; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN MICROARRAY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

EID: 33646801257     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.3.2.207     Document Type: Article

References (77)

1. Boyle P, Ferlay J: Cancer incidence and mortality in Europe, 2004. Ann Oncol. 16, 481-488 (2005).
2. Jemal A, Murray T, Ward E et al.: Cancer statistics, 2005. CA Cancer J. Clin. 55, 10-30 (2005).
3. Hermanek P: pTNM and residual tumor classifications: problems of assessment and prognostic significance. World J. Sung. 19, 184-190 (1995).
4. Ahmed FE: Artificial neural networks for diagnosis and survival prediction in colon cancer. Mol. Cancer 4, 29 (2005).
5. Ahmed FE: Molecular markers that predict response to colon cancer therapy. Expert Rev. Mol. Diagn. 5, 353-375 (2005).
6. Ahmed FE: Development of novel diagnostic and prognostic molecular markers for sporadic colon cancer. Expert Rev. Mol. Diagn. 5, 337-352 (2005).
7. Bustin SA, Dorudi S: Molecular assessment of tumor stage and disease recurrence using PCR-based assays. Mol. Med. Today 4, 389-396 (1998).
8. Ramaswamy S, Ross KN, Lander ES, Golub TR: A molecular signature of metastasis in primary solid tumors. Nature Genet. 33, 49-54 (2003).
9. Ribic CM, Sargent DJ, Moore MJ et al.: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 349, 247-257 (2003).
10. Hawkins NJ, Tomlinson I, Meagher A, Ward RL: Microsatellite-stable diploid carcinoma: a biologically distinct and aggressive subset of sporadic colorectal cancer. Br. J. Cancer 84, 232-236 (2001).
11. Wang Y, Jatkoe T, Zhang Y et al.: Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J. Clin. Oncol. 22, 1564-1571 (2004).
12. Bustin SA, Mueller R: Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis. Clin. Sci. (Lond.) 109, 365-379 (2005).
13. Bustin SA, Mueller R: Real-time reverse transcription PCR and the detection of occult disease in colorectal cancer. Mol. Aspects Med. 27, 192-223 (2006).
14. Hayashi N, Ito I, Yanagisawa A et al.: Genetic diagnosis of lymph-node metastasis in colorectal cancer. Lancet 345, 1257-1259 (1995).
15. Clarke GA, Ryan E, Crowe JP, O'Keane JC, MacMathuna P: Tumor-derived mutated K-ras codon 12 expression in regional lymph nodes of stage II colorectal cancer patients is not associated with increased risk of cancer-related death. Int. J. Colorectal Dis. 16, 108-111 (2001).
16. Anker P, Lefort F, Vasioukhin V et al.: K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. Gastroenterology 112, 1114-1120 (1997).
17. Lecomte T, Berger A, Zinzindohoue F et al.: Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int. J. Cancer 100, 542-548 (2002).
18. Ng EK, Tsui NB, Lam NY et al.: Presence of filterable and nonfilterable mRNA in the plasma of cancer patients and healthy individuals. Clin. Chem. 48, 1212-1217 (2002).
19. Bustin SA, Gyselman VG, Williams NS, Dorudi S: Detection of cytokeratins 19/20 and guanylyl cyclase C in peripheral blood of colorectal cancer patients. Br. J. Cancer 79, 1813-1820 (1999).
20. Wyld DK, Selby P, Perren TJ et al.: Detection of colorectal cancer cells in peripheral blood by reverse-transcriptase polymerase chain reaction for cytokeratin 20. Int. J. Cancer 79, 288-293 (1998).
21. Champelovier P, Mongelard F, Seigneurin D: CK20 gene expression: technical limits for the detection of circulating tumor cells. Anticancer Res. 19, 2073-2078 (1999).
22. Wharton RQ, Jonas SK, Glover C et al.: Increased detection of circulating tumor cells in the blood of colorectal carcinoma patients using two reverse transcription-PCR assays and multiple blood samples. Clin. Cancer Res. 5, 4158-4163 (1999).
23. Bustin SA, Gyselman VG, Siddiqi S, Dorudi S: Cytokeratin 20 is not a tissue-specific marker for the detection of malignant epithelial cells in the blood of colorectal cancer patients. Int. J. Surg. Invest. 2, 49-57 (2000).
24. Bustin SA, Siddiqi S, Ahmed S, Hands R, Dorudi S: Quantification of cytokeratin 20, carcinoembryonic antigen and guanylyl cyclase C mRNA levels in lymph nodes may not predict treatment failure in colorectal cancer patients. Int. J. Cancer 108, 412-417 (2004).
25. Oberg AN, Lindmark GE, Israelsson AC, Hammarstrom SG, Hammarstrom ML: Detection of occult tumor cells in lymph nodes of colorectal cancer patients using real-time quantitative RT-PCR for CEA and CK20 mRNAs. Int. J. Cancer 111, 101-110 (2004).
26. Keilholz U, Willhauck M, Rimoldi D et al.: Reliability of reverse transcription-polymerase chain reaction (RT-PCR)- based assays for the detection of circulating tumor cells: a quality-assurance initiative of the EORTC Melanoma Cooperative Group. Eur. J. Cancer 34, 750-753 (1998).
27. Lacroix J, Doeberitz MK: Technical aspects of minimal residual disease detection in carcinoma patients. Semin. Surg. Oncol. 20, 252-264 (2001).
28. Heid CA, Stevens J, Livak KJ, Williams PM: Real time quantitative PCR. Genome Res. 6. 986-994 (1996).
29. Bustin SA: Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J. Mol. Endocrinol. 25, 169-193 (2000).
30. Bustin SA, Nolan T: Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction. J. Biomol. Tech. 15, 155-166 (2004).
31. Bustin SA: Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J. Mol. Endocrinol. 29, 23-39 (2002).
32. Muller MC, Hordt T, Paschka P et al.: Standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemia. Acta Haematol. 112, 30-33 (2004).
33. Bustin SA: A-Z of quantitative PCR. IUL Press, La Jolla, CA, USA (2004).
34. Afzal MA, Osterhaus AD, Cosby SL et al.: Comparative evaluation of measles virus-specific RT-PCR methods through an international collaborative study. J. Med. Virol. 70, 171-176 (2003).
35. Niesters HG: Quantitation of viral load using real-time amplification techniques. Methods 25, 419-429 (2001).
36. Gabert J, Beillard E, van der Velden VH et al.: Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 17, 2318-2357 (2003).
37. Niesters HG: Molecular and diagnostic clinical virology in real time. Clin. Microbiol. Infect. 10, 5-11 (2004).
38. Bustin SA: Real-time, fluorescence-based quantitative PCR: a snapshot of current procedures and preferences. Expert Rev. Mol. Diagn. 5, 493-498 (2005).
39. Ladanyi A, Soong R, Tabiti K, Molnar B, Tulassay Z: Quantitative reverse transcription-PCR comparison of tumor cell enrichment methods. Clin. Chem. 47, 1860-1863 (2001).
40. Vlems F, Soong R, Diepstra H et al: Effect of blood sample handling and reverse transcriptase-polymerase chain reaction assay sensitivity on detection of CK20 expression in healthy donor blood. Diagn. Mol. Pathol. 11, 90-97 (2002).
41. Max N, Willhauck M, Wolf K et al.: Reliability of PCR-based detection of occult tumor cells: lessons from real-time RT-PCR. Melanoma Res. 11, 371-378 (2001).
42. Zippelius A, Lutterbuse R, Riethmuller G, Pantel K: Analytical variables of reverse transcription-polymerase chain reaction-based detection of disseminated prostate cancer cells. Clin. Cancer Res. 6, 2741-2750 (2000).
43. Vlems FA, Diepstra JH, Cornelissen IM et al.: Limitations of cytokeratin 20 RT-PCR to detect disseminated tumor cells in blood and bone marrow of patients with colorectal cancer: expression in controls and downregulation in tumor tissue. Mol. Pathol. 55, 156-163 (2002).
44. Raggi CC, Verderio P, Pazzagli M et al.: An Italian program of external quality control for quantitative assays based on real-time PCR with Taq-Man probes. Clin. Chem. Lab. Med. 43, 542-548 (2005).
45. Willey JC, Crawford EL, Jackson CM et al: Expression measurement of many genes simultaneously by quantitative RT-PCR using standardized mixtures of competitive templates. Am. J. Respir. Cell Mol. Biol. 19, 6-17 (1998).
46. Crawford EL, Warner KA, Khuder SA, Zahorchak RJ, Willey JC: Multiplex standardized RT-PCR for expression analysis of many genes in small samples. Biochem. Biophys. Res. Commun. 293, 509-516 (2002).
47. Willey JC, Crawford EL, Knight CR et al.: Standardized RT-PCR and the standardized expression measurement center. Methods Mol. Biol. 258, 13-41 (2004).
48. Willey JC, Knight CR, Crawford EL et al.: Use of standardized reverse transcription-polymerase chain reaction and the standardized expression measurement center in multi-institutional trials to develop meaningful lung cancer classification based on molecular genetic criteria. Chest 125, 155S-156S (2004).
49. Pagliarulo V, George B, Beil SJ et al.: Sensitivity and reproducibility of standardized-competitive RT-PCR for transcript quantification and its comparison with real time RT-PCR. Mol. Cancer 3, 5 (2004).
50. Sanchez JA, Pierce KE, Rice JE, Wangh LJ: Linear-after-the-exponential (LATE)-PCR: an advanced method of asymmetric PCR and its uses in quantitative real-time analysis. Proc. Natl Acad. Sci. USA 101, 1933-1938 (2004).
51. Hartshorn C, Anshelevich A, Wangh LJ: Rapid, single-tube method for quantitative preparation and analysis of RNA and DNA in samples as small as one cell. BMC Biotechnol. 5, 2 (2005).
52. Zetter BR: The cellular basis of site-specific tumor metastasis. N. Engl. J. Med. 322, 605-612 (1990).
53. Ramaswamy S, Golub TR: DNA microarrays in clinical oncology. J. Clin. Oncol. 20, 1932-1941 (2002).
54. Shih W, Chetty R, Tsao, MS: Expression profiling by microarrays in colorectal cancer. Oncol. Rep. 13, 517-524 (2005).
55. Alon U, Barkai N, Notterman DA et al.: Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc. Natl Acad. Sci. USA 96, 6745-6750 (1999).
56. Notterman DA, Alon U, Sierk AJ, Levine AJ: Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res. 61, 3124-3130 (2001).
57. Lin YM, Furukawa Y, Tsunoda T et al.: Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas. Oncogene 21, 4120-4128 (2002).
58. Hegde P, Qi R, Gaspard R et al.: Identification of tumor markers in models of human colorectal cancer using a 19,200-element complementary DNA microarray. Cancer Res. 61, 7792-7797 (2001).
59. Kwon HC, Kim SH, Roh MS et al.: Gene expression profiling in lymph node-positive and lymph node-negative colorectal cancer. Dis Colon Rectum 47, 141-152 (2004).
60. Yanagawa R, Furukawa Y, Tsunoda T et al.: Genome-wide screening of genes showing altered expression in liver metastases of human colorectal cancers by cDNA microarray. Neoplasia 3, 395-401 (2001).
61. Bertucci F, Salas S, Eysteries S et al: Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 23, 1377-1391 (2004).
62. Eschrich S. Yang I, Bloom G et al.: Molecular staging for survival prediction of colorectal cancer patients. J. Clin. Oncol. 23, 3526-3535 (2005).
63. Arango D, Laiho P, Kokko A et al.: Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer. Gastroenterology 129, 874-884 (2005).
64. Bustin SA, Dorudi S: The value of microarray techniques for quantitative gene profiling in molecular diagnostics. Trends Mol. Med. 8, 269-272 (2002).
65. Hoos A, Nissan A, Stojadinovic A et al.: Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis. Clin Cancer Res. 8, 3841-3849 (2002).
66. Choi JK, Choi JY, Kim DG et al.: Integrative analysis of multiple gene expression profiles applied to liver cancer study. FEBS Lett. 565, 93-100 (2004).
67. Hosack DA, Dennis G Jr. Sherman BT, Lane HC, Lempicki RA: Identifying biological themes within lists of genes with EASE. Genome Biol. 4, R70 (2003).
68. Choi JK, Yu U, Yoo OJ, Kim S: Differential coexpression analysis using microarray data and its application to human cancer. Bioinformatics 21, 4348-4355 (2005).
69. Hunter K: Host genetics influence tumor metastasis. Nature Rev. Cancer 6, 141-146 (2006).
70. Boedefeld WM 2nd, Bland KI, Heslin MJ: Recent insights into angiogenesis, apoptosis, invasion, and metastasis in colorectal carcinoma. Ann. Surg. Oncol. 10, 839-851 (2003).
71. Al-Mulla F, Keith WN, Pickford IR, Going JJ, Birnie GD: Comparative genomic hybridization analysis of primary colorectal carcinomas and their synchronous metastases. Genes Chromosomes Cancer 24, 306-314 (1999).
72. Baisse B. Bouzourene H, Saraga EP, Bosman FT, Benhattar J: Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma. Int. J. Cancer93, 346-352 (2001).
73. Losi L, Baisse B, Bouzourene H, Benhattar J: Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis 26, 916-922 (2005).
74. Kitahara O, Furukawa Y, Tanaka T et al.: Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia. Cancer Res. 61, 3544-3549 (2001).
75. Hendrix MJ, Seftor EA, Meltzer PS et al.: Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc. Natl Acad. Sci. USA 98, 8018-8023 (2001).
76. Koukourakis MI, Giatromanolaki A, Harris AL, Sivridis E: Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res. 66, 632-637 (2006).
77. Joyce JA: Therapeutic targeting of the tumor microenvironment. Cancer Cell 7, 513-520 (2005).